Logo der Universität Wien

Mag.pharm. Dr. Philipp Buchner

e-mail

Room 2E 446

Tel.: +43-1-4277-55579

Fax: +43-1-4277-9551


Teaching


Research interests

  • clinical & preclinical pharmacokinetics

  • drug-monitoring

  • drug metabolism

  • simulations
  • physiologically-based pharmacokinetics (PBPK)

 


Publications

Journal Articles

  • Buchner P, Sahmanovic A, Schreiber V, Baroian N, Dittrich C, Czejka M: A simple method for comparing enzymatic capecitabine activation in various mono- and combination chemotherapies. Pharmacology 2014; accepted

  • Farkouh A, Scheithauer W, Buchner P, Georgopoulos A, Schueller J, Gruenberger B, Czejka M: Clinical pharmacokinetics of capecitabine in combination with the monoclonal antibody bevacizumab. Anticancer Res 2014, 34: 3669-3673  

  • Czejka M, Ulsperger E, Schnait H, Brumnik T, Schierholz J, Buchner P, Greil R: Evidence for the conversion of docetaxel into 7-epidocetaxel in patients receiving conventional Taxotere® based chemotherapy. J Anal Oncology 2014, 3: 73-78
  • Czejka M, Sahmanovic A, Buchner P, Steininger T, Dittrich C: Disposition of Erlotinib and Its Metabolite OSI420 in a Patient with High Bilirubin Levels. Case Rep Oncol 6:602-608, 2013. (DOI: 10.1159/000357211)
  • Buchner P, Mihola E, Sahmanovic A, Steininger T, Dittrich Ch and Czejka M: Validation of a Simple Assay for the Quantification of the Capecitabine Metabolites 5’–DFCR and 5’–DFUR for Drug Monitoring in Patients Receiving Outpatient Chemotherapy. Anticancer Res 33 (3): 881-886, 2013.

Conference Contributions

  • 2013: Sahmanovic A, Buchner P, Lichtneckert M, Dittrich Ch, Czejka M: Pharmacokinetics of erlotinib and its main metabolite OSI420 in advanced pancreatic cancer patients when combined with escalating doses of capecitabine, P-0042, WCGICT, Barcelona.
  • 2011: Buchner P, Czejka M, Sahmanovic A, Terkola R, Steininger T, Dittrich Ch: Pharmacokinetics and metabolic activation of capecitabine (CCB) in advanced pancreatic cancer when given concomitantly with erlotinib (ERL) and bevacizumab (BVZ), P-0129, WCGICT, Barcelona.

  • 2011: Sahmanovic A, Czejka M, Buchner P, Terkola R, Steininger T, Dittrich Ch Clinical pharmacokinetics of erlotinib in advanced pancreatic cancer patients after single and multiple dose, P-0128, WCGICT, Barcelona

Division of Clinical Pharmacy and Diagnostics
University of Vienna
Althanstraße 14
A-1090 Wien, Austria

T: +43-1-4277-555-01
F: +43-1-4277-9551
E-Mail
University of Vienna | Universitätsring 1 | 1010 Vienna | T +43-1-4277-0